MDS 2023 | Benefits and challenges associated with subcutaneous infusions for Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the benefits and challenges of subcutaneous levodopa delivery for Parkinson’s disease patients. This delivery strategy can potentially target a large proportion of patients and improve their quality of life. However, there are concerns about the cost and availability of the system, as it may only be reimbursed in Western countries. Prof. Antonini emphasizes the global need for continuous levodopa delivery and predicts that if it is successfully implemented in Western countries, patients in underdeveloped areas will also begin to require this treatment. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.